Photodiagnosis and photodynamic therapy · 2026
Clinical efficacy of curettage combined with 5-aminolevulinic acid photodynamic therapy in treating recalcitrant acral warts.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhang Long, He Yang, Yuan Juan, Ding Wen, Lei Xia, Cheng Qionghui, Chen Nian
Аннотация
BACKGROUND AND OBJECTIVES: Viral warts are benign proliferative skin lesions caused by the human papillomavirus (HPV) and are contagious among humans. Currently, there are no effective treatments to address the high recurrence rate of viral warts, presenting challenges in achieving their complete eradication. The aim of this study was to evaluate the efficacy and safety of curettage combined with 5-aminolevulinic acid photodynamic therapy (ALA-PDT) for the treatment of recalcitrant acral warts.
METHODS: Our study was carried out between July 2023 to June 2025, and the clinical data of 50 patients diagnosed with acral warts were retrospectively collected. Patients were assigned to the curettage group (n = 24) or the combination group (n = 26) based on whether they received photodynamic therapy after curettage. The clinical response effects, recurrence rate and adverse reactions of the two groups were observed and compared.
RESULTS: The cure rate in the combination group was 80.8% (21/26), which was significantly higher than 45.8% (11/24) in curettage group. The recurrence rate in the combination group was 19.2% (5/26), which was lower than 54.2% (13/24) in curettage group (P < 0.05). After three months of follow-up, moderate pain was the main adverse reaction in both groups, and no systemic adverse reactions were observed.
CONCLUSION: Our results suggest that curettage combined with ALA-PDT is promising as a safe and effective therapy for patients with recalcitrant acral warts.
METHODS: Our study was carried out between July 2023 to June 2025, and the clinical data of 50 patients diagnosed with acral warts were retrospectively collected. Patients were assigned to the curettage group (n = 24) or the combination group (n = 26) based on whether they received photodynamic therapy after curettage. The clinical response effects, recurrence rate and adverse reactions of the two groups were observed and compared.
RESULTS: The cure rate in the combination group was 80.8% (21/26), which was significantly higher than 45.8% (11/24) in curettage group. The recurrence rate in the combination group was 19.2% (5/26), which was lower than 54.2% (13/24) in curettage group (P < 0.05). After three months of follow-up, moderate pain was the main adverse reaction in both groups, and no systemic adverse reactions were observed.
CONCLUSION: Our results suggest that curettage combined with ALA-PDT is promising as a safe and effective therapy for patients with recalcitrant acral warts.